123 I-血管内皮生长因子结合位点在人类肿瘤细胞的表现特征  

Expression characteristics of 123I-vascular endothelial growth factor-binding sites on tumor cells

作　　者：陈文标[1] 李树人[2] 齐素文[3] 陈德珩[1] 戴勇[1] 

机构地区：[1]暨南大学第二临床学院 深圳市人民医院临床医学研究中心,深圳518000 [2]奥地利维也纳大学核医学部 [3]深圳大学医学院生物医学工程学院

出　　处：《国际肿瘤学杂志》2014年第4期297-301,共5页Journal of International Oncology

基　　金：深圳市科技研发资金国际科技合作项目（ZYA201106030005A）

摘　　要：目的 探索肿瘤血管内皮生长因子（VEGF）受体（VEGFR）在人类肿瘤细胞的表现特征.方法 将123 I-VEGF165和123 I-VEGF121标记于人脐静脉内皮细胞（HUVEC）、人类肿瘤细胞株（HMC-1、A431、KU812、U937、HEP-1、HEP-G2、HEP-3B、Raji）、多种人体肿瘤及邻近的非瘤组织和外周血液细胞.统计特异性结合位点最大结合容量（Bmax）值、解离常数（Kd）以及放射性同位素的50％特异性结合所需浓度（IC50）数值.判断各种细胞与123I-VEGF165和123I-VEGF121结合亲和力、数量、特异性.结果 在HUVEC表面发现两种123I-VEGF165结合位点,而123I-VEGF121是单类结合位点.123I-VEGF121位于特定细胞株（HUVEC、HEP-1、HMC-1）和特殊的早期肿瘤（早期黑色素瘤、乳腺导管内癌、卵巢癌和脑膜瘤）中.与外周血液细胞和非瘤组织相比,肿瘤细胞的VEGFR数量明显较多.在123I-VEGF165标记的VEGFR中,早期黑色素瘤、乳腺导管内癌、肝细胞癌、乳头状甲状腺癌、卵巢癌、肾细胞癌的Bmax值分别为45±13、13±3、25 ±8、5±2、42±12、20 ±6.而在123I-VEGF121标志的VEGFR中,早期黑色素瘤、乳腺导管内癌、卵巢癌的Bmax值分别为30 ±8、8±3、20 ±6.123I-VEGF165和123I-VEGF121与诸多人体肿瘤细胞或组织具有特异性结合能力.与123I-VEGF121相比,123I-VEGF165可与更多不同种类的肿瘤细胞相结合,且容量大.结论 123I-VEGF165可能是肿瘤体内成像的一个潜在有效靶点,有望用于肿瘤的诊断与治疗.Objective To explore the expression characteristics of vascular endothelial growth factor （VEGF） receptor （VEGFR）. Methods The 123I-VEGF16s and 123I-VEGFnl were marked to human umbilical vein endothelial cell （HUVEC） , several human tumor cell lines （HMC-1, A431, KU812, U937, HEP-1, HEP-G2, HEP-3B and Raji） , a variety of human tumors and adjacent non-neoplastic tissues as well as periph- eral blood cells. Then, the specific binding site maximal binding capacity （Bin1） , dissociation constant （Kd） and concentration of 50% required specific binding （ICso） were analyzed. The affinity, quantity and specificity of different cells combined with 123 I_VEGF165 and 123 I_VEGF121 were judged. Results Two kinds of analogous 123I-VEGF165 binding sites on the surface of HUVEC were found. While, there was only one kind of 123 I-VEGF121binding site. 123I-VEGF121 was found on the special cell lines （HUVEC, HEP-1 and HMC-1 ） and special early tumors （early melanoma, ductal breast cancer, ovarian cancer and meningioma）. Compared with peripheral blood cells and adjacent non-neoplastic tissues, the number of VEGFR of tumor cells was bigger. Among the 123 I.VEGF,65 marked VEGFR, the Bin value of early melanoma, ductal breast cancer, hepatocellu- lar carcinoma, papillary thyroid carcinoma, ovarian carcinoma, renal cell carcinoma were 45 ± 13, 13 ± 3, 25±8, 5 ± 2, 42± 12, 20 ±6, respectively. While among the 123 I_VEGF121 marked VEGFR, the Bin= value of early melanoma, ductal breast cancer, ovarian carcinoma were 30±8, 8 ±3, 20 ±6. 1231-VEGF165 and J23I-VEGF121 had specific binding capacity with a variety of human tumor cells and tissues. Compared with 123I-VEGFI21, there were more different kinds of tumor cells could be bound to 123I-VEGF165 with higher capacity. Conclusion 123 I_VEGF165 may be a potential target of tumor imaging in vivo, and it is expected to be used to diagnose and treat tumors.

关 键 词：血管内皮生长因子类 肿瘤 放射性核素成像 

分 类 号：R730.2[医药卫生—肿瘤]